New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:22 EDTINCYIncyte reports Q1 EPS (21c), consensus (18c)
Reports Q1 total revenues $89.8M, consensus $97.19M. The company said, "The increase in net loss in Q1 as compared to the same period of 2013 is primarily due to the company’s broad investment in its clinical pipeline and additional costs related to the commercialization of Jakafi in MF and preparation for the anticipated launch in PV."
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 8, 2014
07:34 EDTINCYIncyte achieves $25M milestone for approval of Jakavi in Japan
Incyte Corporation (INCY) has earned a $25M milestone payment from Novartis (NVS) in connection with the approval of Jakavi in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Novartis also continues to make progress in obtaining formal pricing and reimbursement approval for a third major European country and expects this to occur in the second half of 2014. Once achieved, Incyte will earn an additional $60M milestone payment.
07:17 EDTINCYLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use